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Low risk of cervical cancer during a long period after negative
screening in the Netherlands
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A condition for effective cervical cancer screening is a low incidence of cervical cancer after negative screening compared to that in
the absence of screening. This relative risk was studied for the period 1994–1997 in the Netherlands and compared with previous
studies. All cases of invasive cervical cancer diagnosed from 1994 to 1997 in the Netherlands were related to woman-years at risk,
stratified by age, number of preceding negative screenings and time since the preceding negative screening. These incidence rates
were compared with that before screening started in the Netherlands. The relative risk increases from 0.13 in the first year after
screening to 0.24 after more than 6 years after screening for women with one previous negative screening. These figures reduce to
0.06 and 0.18, respectively, for women with two or more previous screenings. However, these estimates are less favourable when
account is taken of the likely decrease in risk for cervical cancer in the period studied. Our data show a low relative risk of cervical
cancer for several years following the last negative Pap smear. However, the denominator of the relative risk, that is, the incidence
without screening, may have been overestimated. This applies also to the IARC multicountry study, and may have caused too
optimistic expectations about the effectiveness of cervical cancer screening.
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The effectiveness of cervical cancer screening has never been
established by randomised controlled trials. Evidence for mortality
reduction, the primary aim of cervical cancer screening, has come
from studies that compared regions or individuals with different
screening intensities (Clarke and Anderson, 1979; Laara et al, 1987;
van der Graaf et al, 1988). One indicator of such effectiveness is the
incidence of cervical cancer after a negative screen related to that
in the absence of screening. The smaller this relative risk, the
better has screening succeeded in selecting women at low risk of
getting cervical cancer in subsequent years. Combined with the
improvement in prognosis for women with a true positive
screening result, such a selective power warrants a reduction in
incidence and mortality.
The present study estimates the relative risk for cervical cancer
after a negative screen on the basis of nationwide Dutch data. This
risk is determined by the duration of the screen-detectable preclinical
stage and the sensitivity of the test for this stage. The predictive value
of a negative screen for not developing cervical cancer increases with
a longer preclinical duration and a higher sensitivity.
When data from large-scale screening programmes became
available, a working group of the International Agency on
Research for Cancer (IARC) estimated the incidence after a
negative screen, compared to the estimated background incidence
in eight countries, that is, Canada, Scotland, Iceland, Denmark,
Norway, Sweden, Switzerland and Italy (IARC Working Group,
1986a, b). Expectations about the effectiveness of cervical cancer
screening are often based on the results of this ‘classic’ study, and
important models for such screening have been validated using the
IARC results (Eddy, 1987; Gustafsson and Adami, 1990; Gyrd-
Hansen et al, 1995; van Oortmarssen and Habbema, 1995). This
was the rationale for comparing the results of the present study
with those of the IARC study: if the results correspond,
expectations concerning the effects of cervical cancer screening
are reinforced.
MATERIALS AND METHODS
All cytological and histological examinations of the cervix in the
Netherlands up to 31 December 1997 were retrieved from the
Pathological National Automated Archive (PALGA). When this
registry started in 1975 few laboratories participated, but within a
decade a high level of national coverage was achieved. Using the
PALGA identification method (i.e. first four characters of the
family name, date of birth and gender), different examinations of
the same woman could be linked. In this study, all cases of invasive
cervical cancer occurring from 1994 to 1997 were identified by
selecting histologically confirmed diagnoses of invasive cancer
from the database. These include all malignant neoplasms of the
cervix, most of which are squamous-cell carcinomas.
Woman-years were counted for each woman, from each negative
screen until the next negative screen, until the histological
diagnosis of a (precursor of) invasive carcinoma, or until 31
December 1997. A negative screen was defined as an episode
consisting of a cytological or histological examination with a
negative result, or a cytological examination with a positive result
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without a histological confirmation of a (precursor of) invasive
cancer (see appendix and Table 2 in the appendix for definitions).
The invasive cases were related to woman-years at risk, and presented
as the number of cases per 100 000 woman-years at risk. These
incidence rates were stratified by age, number of preceding negative
screenings and the interval since the preceding negative screen.
The incidence of invasive cervical cancer was calculated for
women aged 35– 64 years with one previous negative screen and
with two or more previous negative screenings. This method is
comparable to that of the IARC study. Next, the relative risk for
cervical cancer was calculated by dividing the incidence rate after
screening by the incidence in the absence of screening.
Since this background incidence cannot be observed, it had to
be estimated indirectly. For this, we used the clinical incidence of
invasive cervical cancer in the period 1965–1969, this being the
last period before screening was introduced in the Netherlands.
National incidence figures were based on incidence data of three
regions in the Netherlands (Friesland, The Hague and Rotterdam)
covering together 8% of the women in the Netherlands (Central
Cancer Registry, 1993). Regional differences in cervical cancer
incidence have been accounted for by using the differences
between the age-standardised mortality rate of cervical cancer
for these three regions and for the entire land for the period
1968– 1978 as a proxy.
The identification method used by PALGA (first four characters
of the family name, etc.) is not 100% exclusive and will sometimes
combine two or more women in one identification code. To
investigate the influence of this lack of discriminative power of the
identification key, we also calculated the incidence rates excluding
the examinations of those women with 0.5 and 1% of the most
frequently occurring first four characters of the family name. The
corresponding percentages of women thus excluded from analysis
are 31.7 and 43.5%, respectively.
The lack of discriminative power of the identification key leads
to an upward bias in incidence after a negative screen, because
negative screening results may be erroneously linked to a cancer.
We indeed found that the incidence rate including all women is
about 20% higher after one and two or more negative screenings
than the rate after excluding 0.5% of the most frequent first four
characters of the family name. As the difference in incidence
between excluding 0.5 and 1% of the most frequent first four
characters is very small, in our analyses, we chose to exclude only
those women with 0.5% of the most frequent first four characters
of family name in the corresponding table and figures (Table 1,
Figures 1 and 2). This served to limit the lack of discriminative
power of the identification key while maintaining sufficiently large
numbers on which to base our analysis.
Table 1 Relative risk of cervical cancer [95% confidence interval] after two or more negative screenings
over time since the last negative screening for women aged 35–64 years and the number of actual cancer
cases (1994–1997)
Relative risk
Interval
Incidence in
1965–1969
Projected incidencea
in 1994–1997 in a situation
without screening
Number of
cancer cases
0–6 months 0.12 [0.08–0.17] 0.26 [0.18–0.39] 26
7–12 months 0.06 [0.03–0.10] 0.14 [0.08–0.23] 13
1–2 years 0.08 [0.06–0.12] 0.19 [0.13–0.26] 31
2–4 years 0.15 [0.11–0.19] 0.33 [0.26–0.42] 65
4–6 years 0.20 [0.14–0.29] 0.45 [0.32–0.64] 31
6–10 years 0.18 [0.11–0.30] 0.41 [0.25–0.68] 15
Two different ways of calculating the background incidence (i.e. the denominator of the relative risk) were used (see text).
aBased on the APC analysis of prescreening mortality (see Discussion).
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Figure 2 Relative risk of invasive cervical cancer after negative pap
smears as assessed in the eight countries contributing to the IARC study
(see text), compared with the risk in the Netherlands after one and two
or more negative screens (95% CIs are shown). F+F: IARC, X
two negative smears; - - -J- - -: Netherlands, one negative screen; - - -K- - -:
Netherlands, Xtwo negative screens.
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Figure 1 Incidence of invasive cervical cancer over time since the last
negative screen, for women with one and two or more preceding negative
screenings. The solid line respresents one negative screen and the dashed
line represents two or more negative screens (95% CIs are shown).
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RESULTS
A total of 1648 invasive carcinomas in women aged 35–64 years
were retrieved in the period 1994–1997 in the Netherlands. Of
these carcinomas, 879 were diagnosed without a preceding
negative screen, 376 after one negative screen and 393 after two
or more preceding negative screenings.
Figure 1 shows the incidence of invasive carcinoma per 100 000
woman-years by interval since the last negative screen for women
with one and with two or more negative screenings. In the first
months after negative screening, the incidence of cervical cancer is
relatively high. This may be because the women and/or physicians
were not reassured by the recent (false) negative Pap smear result
(e.g. because of persisting signs or symptoms) and thus elected for
additional diagnostic procedures. After this initial peak, the
incidence is low and will mainly consist of cases of neoplasia
missed at screening. Over time, the incidence increases because of
new lesions that developed after the negative screening.
Figure 2 shows the incidence of invasive cervical cancer over
time since the previous negative screening, compared with the
incidence of invasive cervical cancer in the period 1965–1969 in the
Netherlands, which was 46.1 per 100 000 women-years for women
aged 35–64 years. In the first years, the relative risk is lower after
two or more negative screenings than after only one negative
screening. Figure 2 also compares our incidence data with the IARC
results. In the first years after a negative screen, the relative risk is
comparable in the two studies, but from 4 years onwards the
relative risk is higher in the IARC study than in the Netherlands.
DISCUSSION
As estimated from an age period cohort (APC) analysis of
prescreening mortality rates in the Netherlands, the risk of cervical
cancer decreases sharply for cohorts of women born after 1927
(van Ballegooijen, 1998). Based on these data, the projected
incidence for the period 1994–1997 in the absence of screening on
the basis of these figures was 20.5 per 100 000 woman-years. For
the women born after 1950 this might be an underestimate because
there was an increased risk for cervical cancer in the youngest
cohorts (Beral et al, 1994), whereas we extrapolated the low risk of
the latest cohort for which prescreening mortality rates were
available (born 1940– 1950) to the youngest cohorts. Table 1 gives
the relative risk using the projected incidence for the period 1994–
1997 (from the APC analysis) compared with the incidence just
before screening started (1965–1969). Using the projected
incidence for 1994–1997 results in a factor two higher risk.
Estimation of the background incidence has also proven
problematic in other studies. In the IARC study, some centres
used a case–control approach whereas (as in the present study)
others used a cohort approach. Some cohort studies used the
incidence in women who were never screened as background
incidence, while others used the incidence before screening
became widespread. Both estimates have their problems: that is,
women never attending screening are reported to be at higher risk
for cervical cancer (Berget, 1979; Magnus et al, 1987; van
Oortmarssen and Habbema, 1991) and in several countries a
nonscreening-related decrease in cervical cancer risk in the
considered period is reported (Laara et al, 1987; Cuzick and
Boyle, 1988; van Ballegooijen, 1998). The case–control studies
contributing to the IARC results may also have resulted in an
underestimation of the relative risk because of healthy screenee
bias and frequency bias. Sasieni et al found a factor two higher
relative risk compared with the relative risk of the IARC and the
present study. However, they used a case–control approach with
carefully selected appropriate controls to cases, which may have
reduced the bias (Sasieni et al, 1996). Viikki et al (1999), who
found a three times higher relative risk, used the incidence of the
total population in the screening period. However, because of the
incidence-reducing effect of screening this will be an under-
estimation of the background incidence, which may have led to the
relatively high risks.
Other differences between studies are less important. The IARC
results were presented for two or more previous negative
screenings only, whereas other studies (Mitchell and Giles, 1996;
Sasieni et al, 1996; Viikki et al, 1999) also included a single
previous screening. This latter case leads to a higher incidence and
thus relative risk, especially in the period immediately following a
negative screen (see Figure 2).
In contrast to the four studies discussed above, we considered a
positive smear result that was not followed by a histological
diagnosis as a negative screen. Calculating the relative risk after a
negative Pap smear did not have a strong effect on the results.
As a result of the methodological differences, comparison of the
performance of screening between different countries is difficult.
Nevertheless, for example, the suspected suboptimal performance
of screening in the UK in the 1990s (Raffle et al, 1995; Anonymous,
1998) may have contributed to the high relative risks reported in
that period (Sasieni et al, 1996).
In most of the prominent models on cervical cancer screening
(Eddy, 1987; Gustafsson and Adami, 1990; Gyrd-Hansen et al,
1995; van Oortmarssen and Habbema, 1995), the IARC results have
been used to validate the assumptions of the model regarding the
sensitivity for, and duration of, the preclinical disease stage. If,
however, the IARC results are too favourable (e.g. because of the
underestimation of the background risk) then these models will
also overestimate the effectiveness of cervical cancer screening.
The longer ago screening was started, the greater the uncertainty
will be about the background incidence. As a result, assessment of
the relative risk after negative screening will become increasingly
difficult, that is, more difficult than in the IARC study and the
current study.
In conclusion, our data show that the relative risk for cervical
cancer incidence is low for several years following a negative
screening using the Pap smear. There are strong indications that
Table 2 Definition of primary and secondary examinations
An examination is secondary if in the preceding 48 months:
 there is a histological diagnosis of invasive cervical cancer
 there is a histological diagnosis of preinvasive cancer after which there has not been three cytological examinations with a negative result
 there is a cytological diagnosis of severe dysplasia after which there has not been three cytological examinations with a negative result
 there are at least two cytological diagnoses of light –moderate dysplasia after which there has not been three cytological examinations with a negative result
 there is a histological examination without diagnosis after which there is no histological examination with a negative result or three cytological examinations with a
negative result
 there is a cytological diagnosis of light –moderate dysplasia after which there is no cytological examination with a negative result
 there is an inadequate cytological examination after which there has not been a cytological examination with a negative result
 there is a cytological examination without endocervical cells after which there has not been a cytological examination with a negative result
otherwise an examination is primary
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relative risk estimates are too favourable, because of a too high
estimate of the background incidence. However, even an under-
estimate of the background incidence shows a considerable
reduction in the relative risk after negative screening. The
overestimation also applies to the widely used IARC results, and
may have raised too optimistic expectations about the effectiveness
of cervical cancer screening.
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APPENDIX
Episodes
After linking all examinations belonging to one woman (based on
the first four characters of her family name and date of birth), the
examinations were divided into primary and secondary ones. The
definition of primary and secondary examinations is given in
Table 2. Briefly, an examination is considered to be secondary if in
the 48 months preceding the examination there has been a non-
negative examination result that could have given rise to the
present examination. If not, the examination is a primary one.
Next, series of examinations belonging to one woman were divided
into episodes. An episode is defined as a time period consisting of
a primary examination with (in case the primary examination is
not negative) the accompanying follow-up examinations. If a
primary examination is negative, the episode consists of that
examination only.
Screen-detected and interval carcinomas
An invasive carcinoma was categorised as screen-detected when, in
the episode in which the invasive carcinoma is diagnosed, the
reason for the primary smear was coded as being for screening
purposes. If the reason for the primary smear was not known, the
invasive carcinoma was considered to be screen-detected if no
biopsy was taken at the same time as the primary examination and
if there was no unexpected (from a follow-up point of view)
histological examination in the episode. Otherwise, the invasive
carcinoma was considered to be diagnosed because of symptoms.
Age
Age was determined at the time of the screening examination for
screen-detected carcinomas and at the time of histological
confirmation of invasive cancer for symptomatic cases.
Negative examinations
All primary examinations, both cytological and histological,
without a histological confirmation of a (precursor of ) invasive
cancer in their episode, are counted as a negative examination.
This implies that if the primary examination had a positive result,
this examination is counted as negative examination if no
histological confirmation of the positive smear result takes place.
In case an episode contains a histological diagnosis of a cervical
neoplasia, we assume that the woman will have the normal risk of
getting cervical cancer after the treatment of the cervical
abnormality, and the counting of the negative examinations is
reset to zero.
Interval since the preceding negative examination
The interval since the preceding negative examination is defined
as the time between the last negative primary examination and
the screening examination for screen-detected carcinomas and the
time between the last negative primary examination and the
histological confirmation of invasive cancer for cancers detected
because of symptoms.
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